Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $157 to $115.
Piper Sandler Maintains Overweight on Moderna, Lowers Price Target to $115
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.